



Attorney Docket No. C01037.70025US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert L. Bratzler
Serial No.: 10/017,995
Confirmation No.: 7158
Filed: December 14, 2001
For: INHIBITION OF ANGIOGENESIS BY NUCLEIC ACIDS
Examiner: Nita M. Minnifield
Art Unit: 1645

RECEIVED
DEC 22 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on December 16, 2003.

Maria A. Trevisan, Reg. No. 48,207

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Response to Restriction Requirement

Sir:

In response to the Restriction Requirement mailed from the United States Patent and Trademark Office on October 6, 2003 (Paper No. 10), Applicants hereby request entry of the following election. Applicants respectfully request a two month extension of time and submit the appropriate fee herewith.

BEST AVAILABLE COPY

Election

Applicants hereby elect Group I (claims 1-18), drawn to a method of inhibiting angiogenesis in a subject comprising administering a nucleic acid molecule.

Applicants further make the species election of SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:247, SEQ ID NO:261, SEQ ID NO:262, SEQ ID NO:263, SEQ ID NO:273, SEQ ID NO:300, SEQ ID NO:321 and SEQ ID NO:343 for purposes of examination.

12/19/2003 JBALIAN 00000010 10017995

01 FC:1252


420.00 OP

Remarks

In response to the Restriction Requirement, Applicants have elected Group I.

Having made this election, Applicants expressly reserve the right to file one or more divisional applications on the subject matter of the non-elected claims.

Respectfully submitted,



Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. C1037,70025US00
Dated: December 6, 2003
x01.06.04x

BEST AVAILABLE COPY